Charlottesville, VA – July 26, 2011 – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.  GBM is one of [...]

CHARLOTTESVILLE, VA – May 1, 2011 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat life-threatening unmet medical conditions, today announced that it closed on an additional $2.2 million in private financing during the first quarter of 2011. The financing consisted of convertible notes issued to existing investors. Proceeds will support [...]

“Given the dearth of successful clinical research options in PAD, these study results are exciting,” said study presenter William Hiatt, MD, professor of cardiovascular research in the Department of Medicine, University of Colorado School of Medicine; President of CPC Clinical Research and chairman of the American Heart Association’s Peripheral Vascular Disease Council.

“This non-dilutive award will advance our clinical program and aid us in our mission to introduce approved novel and effective therapies as quickly as possible, providing new hope for patients with PAD, cancer and other conditions related to hypoxia,” said David G. Kalergis, CEO, Diffusion Pharmaceuticals.”